

Nicolas Sluis-Cremer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9047144/publications.pdf>

Version: 2024-02-01

69
papers

2,350
citations

172457

29
h-index

214800

47
g-index

70
all docs

70
docs citations

70
times ranked

2810
citing authors

#	ARTICLE	IF	CITATIONS
1	N348I in the Connection Domain of HIV-1 Reverse Transcriptase Confers Zidovudine and Nevirapine Resistance. <i>PLoS Medicine</i> , 2007, 4, e335.	8.4	151
2	Widespread Fosfomycin Resistance in Gram-Negative Bacteria Attributable to the Chromosomal <i>fosA</i> Gene. <i>MBio</i> , 2017, 8, .	4.1	138
3	Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. <i>Virus Research</i> , 2008, 134, 147-156.	2.2	135
4	Conformational Changes in HIV-1 Reverse Transcriptase Induced by Nonnucleoside Reverse Transcriptase Inhibitor Binding. <i>Current HIV Research</i> , 2004, 2, 323-332.	0.5	133
5	Inhibitors of Histone Deacetylases. <i>Journal of Biological Chemistry</i> , 2011, 286, 22211-22218.	3.4	129
6	Potent Nonnucleoside Reverse Transcriptase Inhibitors Target HIV-1 Gag-Pol. <i>PLoS Pathogens</i> , 2006, 2, e119.	4.7	95
7	Selection of Mutations in the Connection and RNase H Domains of Human Immunodeficiency Virus Type 1 Reverse Transcriptase That Increase Resistance to 3'-Azido-2'-Dideoxythymidine. <i>Journal of Virology</i> , 2007, 81, 7852-7859.	3.4	79
8	Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase. <i>Aids</i> , 2007, 21, 1405-1414.	2.2	68
9	Molecular Mechanism by Which the K70E Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Resistance to Nucleoside Reverse Transcriptase Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 48-53.	3.2	68
10	Novel assay reveals a large, inducible, replication-competent HIV-1 reservoir in resting CD4+ T cells. <i>Nature Medicine</i> , 2017, 23, 885-889.	30.7	68
11	Mutational analysis of Lys65 of HIV-1 reverse transcriptase. <i>Biochemical Journal</i> , 2000, 348, 77-82.	3.7	63
12	Naive CD4+ T Cells Harbor a Large Inducible Reservoir of Latent, Replication-competent Human Immunodeficiency Virus Type 1. <i>Clinical Infectious Diseases</i> , 2019, 69, 1919-1925.	5.8	63
13	E138A in HIV-1 reverse transcriptase is more common in subtype C than B: Implications for rilpivirine use in resource-limited settings. <i>Antiviral Research</i> , 2014, 107, 31-34.	4.1	60
14	Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses. <i>Protein Science</i> , 2007, 16, 1728-1737.	7.6	59
15	Efavirenz Accelerates HIV-1 Reverse Transcriptase Ribonuclease H Cleavage, Leading to Diminished Zidovudine Excision. <i>Molecular Pharmacology</i> , 2008, 73, 601-606.	2.3	57
16	Proteolytic processing of an HIV-1 pol polyprotein precursor: insights into the mechanism of reverse transcriptase p66/p51 heterodimer formation. <i>International Journal of Biochemistry and Cell Biology</i> , 2004, 36, 1836-1847.	2.8	52
17	The Emerging Profile of Cross-Resistance among the Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors. <i>Viruses</i> , 2014, 6, 2960-2973.	3.3	51
18	Structural Basis of Reduced Susceptibility to Ceftazidime-Avibactam and Cefiderocol in <i>Enterobacter cloacae</i> Due to AmpC R2 Loop Deletion. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	51

#	ARTICLE	IF	CITATIONS
19	Glutathione-S-transferase FosA6 of <i>Klebsiella pneumoniae</i> origin conferring fosfomycin resistance in ESBL-producing <i>Escherichia coli</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2460-2465.	3.0	49
20	Efavirenz enhances the proteolytic processing of an HIV-1 pol polyprotein precursor and reverse transcriptase homodimer formation. <i>FEBS Letters</i> , 2005, 579, 379-384.	2.8	46
21	Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules. <i>FEBS Journal</i> , 2002, 269, 5103-5111.	0.2	45
22	Mechanism of allosteric inhibition of HIV-1 reverse transcriptase revealed by single-molecule and ensemble fluorescence. <i>Nucleic Acids Research</i> , 2014, 42, 11687-11696.	14.5	43
23	The 3'-Azido Group Is Not the Primary Determinant of 3'-Azido-3'-deoxythymidine (AZT) Responsible for the Excision Phenotype of AZT-resistant HIV-1. <i>Journal of Biological Chemistry</i> , 2005, 280, 29047-29052.	3.4	38
24	Frequent Emergence of N348I in HIV-1 Subtype C Reverse Transcriptase with Failure of Initial Therapy Reduces Susceptibility to Reverse-Transcriptase Inhibitors. <i>Clinical Infectious Diseases</i> , 2012, 55, 737-745.	5.8	37
25	Establishment and Reversal of HIV-1 Latency in Naive and Central Memory CD4 ⁺ T Cells <i>In Vitro</i> . <i>Journal of Virology</i> , 2016, 90, 8059-8073.	3.4	37
26	Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection. <i>Future Microbiology</i> , 2015, 10, 1773-1782.	2.0	34
27	Structure-Activity Relationships of [2-(5-Bis-O-(tert-butyl dimethylsilyl)- β -D-ribofuranosyl)-3'-spiro-5'-amino-1,2,4-oxathiole-2,2'-dioxido]thymine Derivative and Its Effect on HIV-1 Reverse Transcriptase Dimerization. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 4834-4841.		
28	Mechanism by which a Glutamine to Leucine Substitution at Residue 509 in the Ribonuclease H Domain of HIV-1 Reverse Transcriptase Confers Zidovudine Resistance. <i>Biochemistry</i> , 2008, 47, 14020-14027.	2.5	30
29	Mutational analysis of Lys65 of HIV-1 reverse transcriptase. <i>Biochemical Journal</i> , 2000, 348, 77.	3.7	29
30	Structure and Dynamics of FosA-Mediated Fosfomycin Resistance in <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	28
31	Origin of the plasmid-mediated fosfomycin resistance gene fosA3. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 373-376.	3.0	27
32	N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations. <i>Aids</i> , 2010, 24, 317-319.	2.2	22
33	Identification of mechanistically distinct inhibitors of HIV-1 reverse transcriptase through fragment screening. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 6979-6984.	7.1	22
34	N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations. <i>Aids</i> , 2010, 24, 659-667.	2.2	21
35	Discovery of a Small Molecule Agonist of Phosphatidylinositol 3-Kinase p110 β That Reactivates Latent HIV-1. <i>PLoS ONE</i> , 2014, 9, e84964.	2.5	21
36	Type 1-programmed dendritic cells drive antigen-specific latency reversal and immune elimination of persistent HIV-1. <i>EBioMedicine</i> , 2019, 43, 295-306.	6.1	20

#	ARTICLE	IF	CITATIONS
37	Anti-Human Immunodeficiency Virus Activity, Cross-Resistance, Cytotoxicity, and Intracellular Pharmacology of the 3-azido-2,3-dideoxypurine Nucleosides. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3715-3719.	3.2	19
38	Inhibition of Fosfomycin Resistance Protein FosA by Phosphonoformate (Foscarnet) in Multidrug-Resistant Gram-Negative Pathogens. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	18
39	Inhibitors of Signaling Pathways That Block Reversal of HIV-1 Latency. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	17
40	Temporal transcriptional response to latency reversing agents identifies specific factors regulating HIV-1 viral transcriptional switch. <i>Retrovirology</i> , 2015, 12, 85.	2.0	14
41	Future of nonnucleoside reverse transcriptase inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 637-638.	7.1	14
42	Mutations in the HIV-1 3-Polypurine Tract and Integrase Strand Transfer Inhibitor Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	14
43	<i>In Vitro</i> Cross-Resistance Profiles of Rilpivirine, Dapivirine, and MIV-150, Nonnucleoside Reverse Transcriptase Inhibitor Microbicides in Clinical Development for the Prevention of HIV-1 Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	13
44	Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3-azido-2,3-dideoxypurine nucleosides. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 3832-3844.	5.5	12
45	Zidovudine (AZT) Monotherapy Selects for the A360V Mutation in the Connection Domain of HIV-1 Reverse Transcriptase. <i>PLoS ONE</i> , 2012, 7, e31558.	2.5	12
46	Nonnucleoside Reverse Transcriptase Inhibitors Reduce HIV-1 Production from Latently Infected Resting CD4 ⁺ T Cells following Latency Reversal. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	11
47	Small-Molecule Inhibitor of FosA Expands Fosfomycin Activity to Multidrug-Resistant Gram-Negative Pathogens. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	11
48	Transient kinetic analyses of the ribonuclease H cleavage activity of HIV-1 reverse transcriptase in complex with efavirenz and/or a Î ² -thujaplicinol analogue. <i>Biochemical Journal</i> , 2013, 455, 179-184.	3.7	10
49	Replication Fitness of Multiple Nonnucleoside Reverse Transcriptase-Resistant HIV-1 Variants in the Presence of Etravirine Measured by 454 Deep Sequencing. <i>Journal of Virology</i> , 2013, 87, 8805-8807.	3.4	9
50	Silent mutations at codons 65 and 66 in reverse transcriptase alleviate indel formation and restore fitness in subtype B HIV-1 containing D67N and K70R drug resistance mutations. <i>Nucleic Acids Research</i> , 2015, 43, 3256-3271.	14.5	9
51	Competitive Fitness Assays Indicate that the E138A Substitution in HIV-1 Reverse Transcriptase Decreases <i>In Vitro</i> Susceptibility to Emtricitabine. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2430-2433.	3.2	8
52	Peptides Mimicking the Î ²⁷ /Î ²⁸ Loop of HIV-1 Reverse Transcriptase p51 as Hotspot-Targeted Dimerization Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 811-817.	2.8	8
53	Structure-activity relationships in HIV-1 reverse transcriptase revealed by radiation target analysis. <i>Protein Science</i> , 2003, 12, 2081-2086.	7.6	7
54	Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors. <i>Biomolecules</i> , 2013, 3, 889-904.	4.0	5

#	ARTICLE	IF	CITATIONS
55	B Lymphocytes, but Not Dendritic Cells, Efficiently HIV-1 <i>Trans</i> Infect Naive CD4 ⁺ T Cells: Implications for the Viral Reservoir. <i>MBio</i> , 2021, 12, .	4.1	5
56	Synthesis and Anti-HIV-1 Activity of a Novel Series of Aminoimidazole Analogs. <i>Letters in Drug Design and Discovery</i> , 2010, 7, 318-323.	0.7	5
57	Substrate mimicry: HIV-1 reverse transcriptase recognizes 6-modified-3'-azido-2',3'-dideoxyguanosine-5'-triphosphates as adenosine analogs. <i>Nucleic Acids Research</i> , 2012, 40, 381-390.	14.5	4
58	Nonnucleoside Reverse Transcriptase Inhibitor Hypersusceptibility and Resistance by Mutation of Residue 181 in HIV-1 Reverse Transcriptase. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	4
59	Retroviral RNase H: Structure, mechanism, and inhibition. <i>The Enzymes</i> , 2021, 50, 227-247.	1.7	4
60	Molecular mechanism of HIV-1 resistance to 3'-azido-2',3'-dideoxyguanosine. <i>Antiviral Research</i> , 2014, 101, 62-67.	4.1	3
61	Therapeutic Approaches to Eradicate Latent HIV-1 in Resting CD4 ⁺ T Cells. <i>Current Topics in Medicinal Chemistry</i> , 2015, 16, 1191-1197.	2.1	3
62	Toward a Functional Cure for HIV-1 Infection: The Block and Lock Therapeutic Approach. <i>Frontiers in Virology</i> , 0, 2, .	1.4	3
63	Novel high-throughput screen identifies an HIV-1 reverse transcriptase inhibitor with a unique mechanism of action. <i>Biochemical Journal</i> , 2014, 462, 425-432.	3.7	2
64	Radiation Target Analyses of DNA Template/Primer Complexes. <i>Biophysical Journal</i> , 2006, 90, L61-L63.	0.5	1
65	The Base Component of 3'-Azido-2',3'-Dideoxynucleosides Influences Resistance Mutations Selected in HIV-1 Reverse Transcriptase. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3758-3764.	3.2	1
66	Large Multidomain Protein NMR: HIV-1 Reverse Transcriptase Precursor in Solution. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9545.	4.1	1
67	Retroviral reverse transcriptase: Structure, function and inhibition. <i>The Enzymes</i> , 2021, 50, 179-194.	1.7	1
68	Relative domain orientation of the L289K HIV-1 reverse transcriptase monomer. <i>Protein Science</i> , 2022, 31, e4307.	7.6	1
69	HIV-1 Resistance to the Nonnucleoside Reverse Transcriptase Inhibitors. , 2017, , 521-533.		0